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Type 1 diabetes (T1D) is characterized by a progressive
destruction of pancreatic beta-cells that results in absolute
insulin deficiency and the need for daily insulin treatment.
However, the auto-inflammatory nature of the disease has
been recently demonstrated by understanding the precise
cellular/molecular mechanisms of type 1 diabetes’ aetiology
and progression. Studies in NOD mice have shown that
the disease occurs as consequence of a breakdown in the
immune-system balance. Although the detection of islet
specific auto antibodies in sera from humans with T1D
was the first sign of an autoimmune disease, there is strong
evidence in both, mice and humans that auto-reactive T
cells play a prominent role in disease onset and progres-
sion. Destruction of beta-cells is mainly due to the secre-
tion of powerful pro-inflammatory cytokines, such as
Interleukine -1 beta (IL-1b), tumor-necrosis-factor alpha
(TNFa) and interferon gamma(IFNg). Recent studies have
shown that Foxp3 regulatory T cells’ (Treg) activity is
diminished, which affects the fine balance of the peripheral
self-tolerance and immune activation.
Another key concept is the fact that adult endocrine
pancreas, like most tissues is dynamically regulated by
expansion and reduction mechanisms. There is enough
evidence for beta-cell regeneration in animal models.
In humans, it is well-accepted that beta-cell regeneration
occurs permanently during life and it depends on the
current metabolic demand or pancreatic injury. At dia-
betes clinical onset, beta-cell dysfunction/destruction
has overcome beta-cell regeneration and consequently
hyperglycaemia occurs.
These findings suggest that immunomodulatory agents
directed to the immune pathogenesis of T1D might
enable preservation of insulin-secreting cells. Besides,
induction of endogenous beta-cell regeneration and
beta-cell replacement are promising strategies to attain
insulin independence.
Nevertheless, specific immunological markers urge to
be identified in order to assess the immunologic stage of
the disease. These might enable therapeutic interventions
targeting restoration of the immune balance, stimulation
of beta-cell regeneration and thereby endogenous insulin
secretion. Similar to neoplastic and HIV-associated dis-
eases, the successful combination of drugs set a light in
the tunnel leading to the cure of diabetes.
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